TCT: Ticagrelor Monotherapy Within One Month of DAPT Noninferior to Continued DAPT
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 27, 2023 -- For patients with acute coronary syndrome (ACS), stopping dual antiplatelet therapy (DAPT) within one month for ticagrelor monotherapy is noninferior and superior to 12 months of ticagrelor-based DAPT, according to a study published online Oct. 25 in Circulation to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 23 to 26 in San Francisco.
Sung-Jin Hong, M.D., from Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a randomized, open-label, noninferiority trial involving 2,850 patients with ACS who underwent drug-eluting stent implantation at 24 centers in South Korea and were randomly assigned to receive ticagrelor monotherapy (90 mg twice daily) after less than one month of DAPT or 12 months of ticagrelor-based DAPT (1,426 and 1,424 patients, respectively).
The researchers found that the primary end point of net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at one year after the index procedure in the intention-to-treat population occurred in 2.8 and 5.2 percent of patients in the group receiving ticagrelor monotherapy after less than one month of DAPT and the ticagrelor-based 12-month DAPT group, respectively (hazard ratio, 0.54). Major bleeding occurred significantly less often in the group receiving ticagrelor monotherapy after less than one month of DAPT versus the 12-month DAPT group (1.2 versus 3.4 percent; hazard ratio, 0.35).
"The significant reduction in major bleeding in the ticagrelor monotherapy after <1-month DAPT group was the primary component of the composite outcome driving these findings," the authors write.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Coronary Artery Vessel Wall Thickness Increased for People Living With HIV
TUESDAY, April 16, 2024 -- Asymptomatic people living with HIV (PLWH) with a low risk for cardiovascular disease have increased coronary artery vessel wall thickness (VWT)...
Etidronate Beneficial for Arterial Calcification Due to CD73 Deficiency
TUESDAY, April 9, 2024 -- For patients with arterial calcification due to deficiency of CD73 (ACDC), etidronate may slow progression of vascular calcification in the lower...
ACC: Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
MONDAY, April 8, 2024 -- Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.